Outset Medical, Inc. (NASDAQ:OM) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Outset Medical, Inc. (NASDAQ:OM) have been given a consensus rating of “Moderate Buy” by the five research firms that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, two have given a buy rating and one has given a strong buy rating to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $10.00.

A number of equities research analysts have issued reports on OM shares. BTIG Research cut their price target on Outset Medical from $17.00 to $15.00 and set a “buy” rating for the company in a research note on Thursday, February 12th. Royal Bank Of Canada reiterated a “sector perform” rating and issued a $7.00 price objective on shares of Outset Medical in a research note on Wednesday, December 17th. Weiss Ratings reissued a “sell (e+)” rating on shares of Outset Medical in a report on Monday, December 29th. Stifel Nicolaus reduced their target price on shares of Outset Medical from $14.00 to $8.00 and set a “buy” rating for the company in a report on Wednesday, January 7th. Finally, Wall Street Zen cut shares of Outset Medical from a “hold” rating to a “sell” rating in a report on Sunday, February 8th.

Outset Medical Stock Performance

Shares of OM opened at $3.26 on Monday. The firm has a market capitalization of $59.69 million, a P/E ratio of -0.48 and a beta of 2.13. The company has a debt-to-equity ratio of 0.76, a current ratio of 6.67 and a quick ratio of 5.40. Outset Medical has a one year low of $3.00 and a one year high of $21.98. The business has a fifty day moving average of $4.25 and a 200 day moving average of $7.86.

Insider Transactions at Outset Medical

In other news, General Counsel John L. Brottem sold 9,314 shares of the company’s stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $5.12, for a total value of $47,687.68. Following the completion of the sale, the general counsel directly owned 36,957 shares in the company, valued at $189,219.84. This represents a 20.13% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Leslie Trigg sold 11,794 shares of the firm’s stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $5.12, for a total value of $60,385.28. Following the completion of the transaction, the chief executive officer directly owned 107,823 shares in the company, valued at approximately $552,053.76. This represents a 9.86% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 40,910 shares of company stock worth $193,040 in the last three months. Corporate insiders own 2.40% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Geode Capital Management LLC increased its holdings in Outset Medical by 955.9% in the 2nd quarter. Geode Capital Management LLC now owns 415,552 shares of the company’s stock worth $7,984,000 after acquiring an additional 376,196 shares in the last quarter. Police & Firemen s Retirement System of New Jersey purchased a new position in Outset Medical during the second quarter valued at approximately $78,000. Ensign Peak Advisors Inc boosted its position in shares of Outset Medical by 272.4% in the second quarter. Ensign Peak Advisors Inc now owns 314,522 shares of the company’s stock worth $6,042,000 after purchasing an additional 230,065 shares during the period. JPMorgan Chase & Co. boosted its position in shares of Outset Medical by 662.8% in the second quarter. JPMorgan Chase & Co. now owns 8,452 shares of the company’s stock worth $162,000 after purchasing an additional 7,344 shares during the period. Finally, Legal & General Group Plc purchased a new stake in shares of Outset Medical in the second quarter worth $34,000.

About Outset Medical

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.